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the Committee for technologies that ultimately did not receive positive endorse-
ment due to clinical benefit or cost considerations. ConClusions: The MTEP is 
the most commonly used process to assess routed technologies and the major-
ity of MTEP evaluations have resulted in positive endorsement. The MTEP process 
assigns equal prominence to healthcare system and patient benefits, with decisions 
being based on the full body evidence available for a technology. However, where 
evidence of clinical effectiveness was associated with uncertainty, the influence of 
demonstrated healthcare system benefits appeared to have limited effect on final 
decision-making.
PMD131
The IMPacT Of Self-MOnITOrIng Of BlOOD glucOSe (SMBg) On 
PreScrIPTIOn cOSTS In newly TreaTeD TyPe 2 DIaBeTeS MelITuS (T2DM): 
a reTrOSPecTIve cOhOrT analySIS
Grimes RT, Bennett K, Henman M
Trinity College Dublin, Dublin, Ireland
objeCtives: To describe the use of self-monitoring of blood glucose (SMBG) in a 
cohort of newly treated T2DM subjects and to assess the contribution of SMBG on 
overall antidiabetic and cardiovascular disease prescription costs. Methods: A 
population based retrospective cohort study was conducted using the Irish national 
pharmacy claims database. Newly treated T2DM patients were identified for 2012 
as being initiated on oral antidiabetic monotherapy and having received no anti-
diabetic therapy in the previous year. Subjects were followed for one year post 
treatment initiation. The association between prescription costs and SMBG was 
assessed using generalised linear model with gamma family and log link functions 
to handle the right skew of the data adjusting for various demographic and treat-
ment factors. Cost ratios and 95% CIs were obtained from this analysis and were 
used to determine the contribution of SMBG to prescription costs. Results: A total 
of 12,941subjects were eligible for the study with 64% of subjects using SMBG. SMBG 
use was highest in subjects aged 40-49 years (71%) and decreased with age, with 
48% of subjects aged 80-89 years using SMBG. Most subjects used SMBG greater than 
once a week but less than daily (41%) or daily and more frequently (51%). Use of 
SMBG resulted in dispensing costs that were overall 81% higher than those without 
SMBG use (95% CI 1.76, 1.92). ConClusions: Use of SMBG in newly treated T2DM 
was high including the frequency of use and resulted in high associated costs. 
SMBG represents a significant financial component in diabetes care, yet previous 
work has shown no clear benefit in newly treated type 2 diabetes patients on oral 
therapy. There is the potential for cost savings by introducing a review or limit on 
the amount of SMBG tests available to newly treated T2DM patients.
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acceSSIng The MeDIcal DevIceS MarkeT In egyPT anD SauDI araBIa: a 
SySTeMaTIc revIew Of POlIcIeS anD regulaTIOnS
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objeCtives: The objective of this research is to provide an overview of the regu-
latory process of medical devices market access in Egypt and Saudi Arabia. The 
research paper identifies regulatory institutions, processes, and policy framework 
of the national medical devices policy agenda of Egypt and Saudi Arabia respec-
tively. Methods: A systematic search of the literature for medical device regula-
tory information was performed, in academic journals and in relevant regulatory 
authorities’ data sources (Egyptian Drug Authority and Saudi FDA web portals). The 
following databases were searched: PubMed (Medline), Science Direct (EMBASE), 
Scopus and the Arabic database Al Manhal. The search methodology employed was 
in line with PRISMA guidelines. The search language was limited to English and 
Arabic. Results: In total, 41 records were included in the qualitative synthesis 
of this review. The governance, process and implementation of medical devices 
market access have been analyzed in detail. The policy framework of both countries 
is adopted from the International Medical Device Regulatory forum and certain 
reference countries. Concerning products’ technical requirements, direct testing 
of medical devices is not required. However, documentary evidence of a medical 
device’s authorization to be sold in a reference country is mandatory. Challenges 
are related to the interim nature of medical devices legislation in both countries, 
presence of a considerable degree of corruption. In addition there is a lack of trans-
parency and electronic databases, especially in Egypt. ConClusions: In both Saudi 
Arabia and Egypt, medical devices market access is straightforward if there is proof 
of authorization to sell a product in a reference country. However, this system has 
disadvantages in terms of safeguarding patient safety and enabling fast access of 
innovations. Lack of transparency, incomplete regulations, corruption, and a lack of 
comprehensive policy for medical devices are challenges faced by both countries.
PMD133
IDenTIfyIng OPPOrTunITIeS fOr value-BaSeD cOnTracTIng fOr 
MOlecular DIagnOSTIcS aS a MeanS TO IMPrOve OuTcOMeS Of hOSPITal 
acquIreD InfecTIOnS
DiPaolo A, Marcarelli AD, Girardi M
GfK, WAYLAND, MA, USA
objeCtives: Hospital acquired infections (HAIs) can have a serious impact on 
both clinical and economic outcomes. As a result, hospitals implement infec-
tion control (IC) policies to prevent and reduce the transmission of HAIs includ-
ing various approaches to screening and testing incoming or admitted patients. 
Early identification of HAIs is key to limiting their clinical and economic impact. 
Molecular diagnostics (MDx) have the potential to improve IC strategies by quickly 
and accurately identifying patients with suspected or confirmed infections. To 
increase adoption of this technology, both MDx manufacturers and hospital qual-
ity stakeholders have expressed interest in value-based contracting for HAI tests. 
eligibility, order, delivery and invoicing) in an integrated manner in order to easily 
activate new market opportunities from the perspective of Companies, Payers and 
Patients. By defining appropriate minimum datasets, it is possible to involve all 
stakeholders obtaining systematic, homogeneous and high-quality real-world data 
on the use and appropriateness of such devices. ConClusions: The introduction of 
online integrated and shared infrastructures allows to activate common processes 
among Payers and Companies in the challenge of introducing innovative therapies 
and devices in a strained macroeconomic scenario, with the aim to simplify market 
access, facilitate transparency, monitor related costs, while enabling the collection 
of Healthcare Big Data for scientific purposes.
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whaT IS ce MarkIng? hOw TechnOlOgIeS are claSSIfIeD, anD hOw TO 
navIgaTe The SySTeM
Hill D, Stewart D, Balman E
MAP BioPharma Limited, Cambridge, UK
objeCtives: Affixing a CE mark to a product means that the manufacturer is 
declaring that the product meets all legal requirements as well as conforming 
to relevant product safety directives in the EU. CE marking is mandatory, but 
only applies to products that are covered by the subject matter of one or more 
of the New Approach Directives. We aim to clarify the process for obtaining a CE 
mark. Methods: Published reviews, our experience and government and industry 
records were used to outline the complexities of this process, including how to 
determine the relevant type of classification and the steps that need to be taken to 
gain a CE Mark. Results: Medical devices fall into three categories, each of which 
are governed by a different EU directive: Directive of Active Implantable Medical 
Devices (90/385/EEC), Medical Devices Directive (93/42/EEC), and Directive of in Vitro 
Diagnostic Medical Devices (98/79/EC). Each one will encompass guidelines relating 
to an individual product and whether it is required to bear a CE mark. Once a CE 
Mark has been obtained a ‘declaration of conformity’ must be signed before you 
can place the CE mark on your product. This states that the manufacturer takes 
sole responsibility for the conformity within all the legal requirements to achieve 
a CE mark. CE marking means that the product can be marketed anywhere in the 
EU. ConClusions: A CE mark states that a product has been assessed before being 
placed on the market and satisfies legislative requirements of the applicable EC 
directives. It ensures that a product has ‘free-movement’ within the EU as well as 
permitting the ‘withdrawal of products’, which do not conform. More and more 
products are required to have a CE mark if they want to gain access to EU market.
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when IS a BOne fracTure nO lOnger “freSh”?
Scott RA, Jones J, Steen RG
Bioventus LLC, Durham, NC, USA
objeCtives: Robust literature demonstrates the clinical value of low-intensity 
pulsed ultrasound (LIPUS) in the treatment of fresh bone fractures. However, each 
published study used an arbitrary time post-fracture to define a “fresh fracture” for 
study inclusion. In the absence of an accepted clinical definition of fresh fracture, 
many third-party payers have adopted study inclusion criteria as de facto defini-
tions of fresh fracture. Yet exclusion of older fractures may deny access to patients 
who could benefit from LIPUS. We pooled data from patients in a post-market LIPUS 
registry required by the Food & Drug Administration to analyze the inflection point 
at which fracture heal rates begin to decline. Methods: Patients are evaluated if the 
following data are known: days to LIPUS treatment; days on LIPUS treatment; and 
outcome of treatment (Heal / Fail). We present data from 7,117 patients treated with 
LIPUS within 365 days of fracture. We plot (Heal rate) vs. (Days to LIPUS treatment), 
to determine the inflection point at which Heal rate begins to decline. Results: 
Heal rate (Number of patients healed / Number of patients treated) did not differ 
significantly or clinically for at least 10 weeks following fracture. In 284 fracture 
patients who began LIPUS within 1 week of fracture, the heal rate was 97.2% (276 
healed / 284 treated). In 246 patients who began LIPUS treatment 10 weeks after 
fracture, the heal rate was 97.6% (240 healed / 246 treated). There may be a decrease 
in heal rate after 10 weeks, but the heal rate for patients at week 12 was 95.6% (195 
healed / 204 treated). ConClusions: Heal rate with LIPUS was ~97% for ≤ 10 weeks 
following fracture. Many patients who could benefit may be unnecessarily excluded 
from treatment by payer guidelines. We will evaluate heal rate bone-by-bone (tibia, 
femur, humerus, radius, metatarsal) using this method.
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The MeDIcal TechnOlOgIeS evaluaTIOn PrOgraMMe (MTeP): an 
analySIS Of nOTIfIcaTIOnS, DecISIOn-MakIng anD The InTerPreTaTIOn 
Of claIMeD healThcare SySTeM BenefITS
Murray G1, Crowe L2, Howells R1
1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK
objeCtives: Firstly, to identify what proportion of medical technologies notified to 
the National Institute for Health and Care Excellence’s (NICE) Medical Technologies 
Appraisal Committee (MTAC) are selected for evaluation by the MTEP. Secondly, to 
analyse the MTEP Committee’s interpretation of claimed healthcare system benefits 
and identify the influence of these benefits on decision-making. Methods: The 
NICE website was used to identify: technologies considered by the MTAC up to May 
2015; the routing information for each technology; the healthcare system benefit 
claims and decision data for all technologies routed to the MTEP. The healthcare 
system benefit claims were categorised according to criteria listed in the NICE MTEP 
methods guide to facilitate identification of any association between the type of 
benefit claimed and the decision outcome. The decision-making committee’s con-
clusions on the claimed healthcare system benefits were interpreted. Results: 
By May 2015, the MTAC at NICE had considered 157 products, of which 99 were not 
selected for evaluation. Of the 58 products selected for evaluation, 35 were routed to 
the MTEP. Seventy-one per cent of MTEP decisions endorsed technology adoption. 
There have been instances of claimed health system benefits being accepted by 
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unheated CO2 (U-CO2) in laparoscopic patients. Efficacy data were derived from 
a published randomised controlled trial reporting on the proportion of patients 
with hypothermia, a US database analysis of hypothermia patients for open sur-
gery, and from an unpublished UK NHS before and after study of laparoscopic sur-
gery patients. Other parameter inputs were obtained from published literature. 
Deterministic and probabilistic sensitivity analyses were conducted to assess the 
robustness of results. Scenario analyses were undertaken to explore structural 
uncertainty within the model. Results: The use of WH-CO2 dominated standard 
care, as it was both cost saving and generated greater QALYs, for both open and lapa-
roscopic surgery patients over a one year time horizon. Results varied by the number 
of patients undergoing surgery per humidifier per year. Based on 250 patients using 
the humidifier each year over a five year lifetime of the humidifier, WH-CO2 domi-
nated no insufflation in open surgery patients in 71% of model iterations and domi-
nated U-CO2 in laparoscopic surgery in 98% of model iterations. WH-CO2 remained 
the cost-effective treatment option at a willingness-to-pay threshold of £20,000 per 
QALY throughout all scenario and sensitivity analyses considered, provided 10 or 
more patients used each humidifier over its life span. ConClusions: The analy-
ses conducted suggest that based upon the currently available clinical evidence, 
WH-CO2 is a cost-effective use of resources for patients undergoing either open or 
laparoscopic colorectal surgery within the UK NHS.
PMD137
ecOnOMIc analySIS Of evarreST® SealanT MaTrIx cOMPareD wITh 
STanDarD Of care In Severe SOfT TISSue SurgIcal BleeDIng: a unITeD 
kIngDOM hOSPITal PerSPecTIve
Jamous N1, Carter S2, Ferko N3, Hogan A3, Corral M4
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tis-
sue surgical bleeding in the United Kingdom (UK). Methods: An economic model 
quantified 30-day cost impact of EVARREST® from a UK hospital perspective. 
Severe soft tissue bleeding trial resources included quantity of initial treatment, re-
treatment, surgery time, transfusion risk, amount transfused, and hospitalization 
(ICU and ward stay). SoC was composed of Surgicel® (88%) and conventional meth-
ods (e.g., manual compression). The surgical analysis included resources clinically 
related to the significant hemostasis benefit of EVARREST®(i.e., initial and re-
treatment, operating time, transfusion). A hospital analysis included all resources 
collected. Published data on UK costs were applied to resource use. A subgroup 
analysis was conducted for patients meeting coagulopathic criteria based 
on abnormal values for at least one of the trial coagulation parameters col-
lected. Results: The surgical base-case analysis predicted that EVARREST® 
cost was offset by averted resource use with per patient cost impact of £464 
(sensitivity range: -£422 to £1,351) vs. SoC. The hospital analysis predicts fur-
ther resource reduction with EVARREST® leading to cost-savings of £1,006 per 
patient (sensitivity range: -£2,546 to £534). In coagulopathic patients, the results 
dramatically improved, with the surgical and hospital analysis both showing 
cost-savings of £2,526 and £5,720 per patient, with EVARREST®vs. SoC respec-
tively. ConClusions: In problematic bleeding situations, EVARREST® may result 
in important cost savings for hospitals, in addition to meeting an important unmet 
need. This analysis suggests results may depend on bleeding type, with increased 
benefit in challenging (i.e., coagulopathic) bleeding patients. Further study is 
needed to confirm findings.
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MeDIcal DevIceS: why DO SOMe Pay MOre Than OTherS DO? analySIS Of 
PrIce varIaTIOn In french PuBlIc hOSPITal In 2013
Grande M1, Le Louette AC2, Hehn M2, Bertrand L2, Paubel P3
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Cité, Paris, France; Health Law Institute, Inserm, UMR S 1145, Paris Descartes Université, 
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objeCtives: The aim of this benchmarking study is to provide a detailed analysis of 
medical devices (MD) price and to identity what drove price dispersion. Methods: 
A large panel of MD level price data was collected in 3 French public healthcare 
institutions and 10 centralized purchasing groups (representing 37% of french public 
hospitals). MD were selected according to the Pareto law (20% of the MD represent 
80% of the expenditure) and expert opinion to ensure that each MD had sufficiently 
large demand. Several factors were considered such as volume purchased, affiliation 
to a purchasing group, procurement procedure and contract start date. Results: 
Finally, 18 MD were retained following up on the provided answers (5 elastic band-
ages, 2 implants, 8 common MD and 3 captive MD). In terms of pricing, results 
between hospitals being close for similar quantifies and none can be defined as 
the benchmark leader. Rebates are a common mechanism and the level of discount 
depends on the MD considered and type of funding (activity based or additional 
payments). Open public tenders are the most commonly procurement procedure 
used, whereas negotiated procedures are more efficient for captive MD. There is 
practically no relationship between volume purchased and purchased prices. MD 
price can change over time and the relevance of the contract start date is con-
firmed: older the contract is, cheaper is the price for some MD, or on the contrary 
for others. ConClusions: There is no connection between catalogue prices and 
purchased prices especially for MD paid by activity based payment (discount rates 
can reach 50% to 90%). As the volume effect has no evident impact on MD discounts, 
the advantage of joining a centralized purchasing group has not been confirmed. 
The crucial factors are mainly the MD considered, the contract start date and the 
procurement procedure.
To further understand this opportunity, this research sought to identify key IC 
practices that would be impacted by MDx testing and could support improved HAI 
outcomes. Methods: Telephone-based primary research was conducted with 
34 hospital quality and IC stakeholders across the US and UK to understand the 
impact of HAIs, current IC practices, quality metrics, outcomes and opportunities 
for MDx. Desk research was carried out to further investigate hospital IC strategies 
and reporting metrics. Results: Hospitals have implemented a variety of strate-
gies aimed at reducing and preventing the incidence of HAIs. Hospitals assess the 
success of their IC strategies by benchmarking their infection rates against national 
or regional reports and measuring compliance with certain IC protocols. There are 
various IC practices that could be impacted by MDx testing such as patient isolation 
and timely administration of targeted antibiotic therapy; however, metrics associ-
ated with these protocols are generally not reported. ConClusions: Primary and 
secondary research findings suggest that compliance with IC protocols is critical to 
improving HAI outcomes. Expanding hospital quality reporting metrics to include 
factors impacted by MDx could support value-based contracting efforts by asso-
ciating testing with improved IC practices, and will ultimately support improved 
HAI outcomes.
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BuDgeT IMPacT analySIS Of BIOaBSOrBaBle Drug-eluTIng SInuS 
IMPlanTS fOr enDOScOPIc SInuS Surgery
Rudmik L1, Mallow PJ2, Palli S2, Rizzo JA3
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Cincinnati, OH, USA, 3Stony Brook University, Stony Brook, NY, USA
objeCtives: Bioabsorbable drug-eluting sinus implants (BDESI) inserted dur-
ing endoscopic sinus surgery (ESS) have been shown to improve post-operative 
outcomes in the management of refractory chronic rhinosinusitis (CRS) through 
reduced post-operative scarring, inflammation, polyposis and middle turbinate 
lateralization. This study estimated the incremental budgetary impact of incorpo-
rating BDESI in CRS patients undergoing ESS. Methods: A budget impact model 
(following ISPOR’s Good Practice Report) was developed from the perspective of the 
United States payor/self-insured employer. The model was created to be dynamic 
and adaptable to different countries. Estimates of the prevalence of CRS; rates of 
ESS; and effectiveness outcomes; along with direct and indirect costs from CRS 
were obtained from a best-evidence systematic review of the published literature. 
A total population of 1.5 million members was used for the analysis. All cost data 
obtained from the published literature were adjusted to April 2015 US dollars 
using the medical care component of the Consumer Price Index. The comparator 
groups were ESS with BDESI compared to the current clinical peri-/ post-opera-
tive care. Primary outcome was the incremental budget impact reported using 
per-member-per-month (PMPM) costs. Scenario-based, probabilistic, and one-
way sensitivity analyses were performed. Results: For a US payor/self-insured 
employer health plan of 1.5 million members, the incremental PMPM impact of 
BDESI was estimated to range from -$0.009 to $0.09. The results varied based on 
the parameters included in the individual scenario. Sensitivity analyses revealed 
these findings to be robust to specified parameter value ranges. ConClusions: 
Previously published studies have documented the clinical benefits of BDESI. This 
study has demonstrated the use of BDESI during ESS procedures has negligible 
impact on the healthcare budget. Additional research is necessary to determine 
the budget impact for different countries based on the same factors described 
within this analysis.
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re-uSe Of InSulIn SyrInge neeDleS anD ITS exTra DISeaSe BurDen fOr 
DIaBeTIc PaTIenTS In BeIjIng
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objeCtives: To investigate the situation of disposable insulin syringe needles 
re-use in the diabetic patients in Beijing and the safety problems due to re-use 
as well as the extra disease burden. Methods: Use the semi-constructed ques-
tionnaire to investigate how the insulin injection needles were re-used and its 
disease burden on diabetic patients who had been treated by insulin injection 
for at least half a year in 21 hospitals in Beijing. Results: 45.25% of the insulin 
syringe needles were obtained from the pharmacies outside hospitals and the 
average price was 2.76 RMB per piece. Only less than 2% of the diabetics use new 
disposable needle per injection and 30.52% of them only changed their needles 
once per week. The main cause of 84.53% of the diabetics was cost saving. More 
than half of the surveyed diabetics got needle-injection-related hurts such as 
Lipohypertrophy and skin infection. 61.98% got hypoglycemia symptoms in the 
last 3 months. It was estimated that the extra disease burden resulted from the 
safety problems of insulin syringe needles re-use was 458.74 RMB per patient per 
year. ConClusions: At first health education should be enhanced on how to use 
the insulin syringe needles correctly and take it into consideration of bring the 
insulin syringe needles into insurance reimbursement list at appropriate time to 
alleviate the economic burden of the diabetics.
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cOST-effecTIveneSS Of lOcal InSufflaTIOn Of warM huMIDIfIeD cO2 
DurIng OPen anD laParOScOPIc cOlOrecTal Surgery
Jenks M, Taylor M, Shore J
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objeCtives: To determine the cost-effectiveness of local insufflation (via a humidi-
fier) of warm humidified CO2 (WH-CO2) compared with standard care in patients 
undergoing open or laparoscopic colorectal surgery. Methods: A decision-analytic 
model was developed to estimate the costs and quality-adjusted life-years (QALYs) 
associated with open and laparoscopic colorectal surgery from a UK NHS perspec-
tive. WH-CO2 was compared with no insufflation in open surgery patients and with 
